Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1055/s-0034-1387825 http://scihub22266oqcxt.onion/10.1055/s-0034-1387825 C4169098!4169098!25317032     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Angiol 2014 ; 23 (3): 193-6 Nephropedia Template TP {{tp|p=25317032|t=2014. Edaravone Injected at the Start of Reperfusion Suppresses Myonephropathic Metabolic Syndrome in Rats |pdf=|usr=}}{{25317032}} gab.com Text Edaravone Injected at the Start of Reperfusion Suppresses Myonephropathic Metabolic Syndrome in Rats JO: Int J Angiol http://www.kidney.de/pget.php?&tw=1&pmid=25317032 #FOAvip The purpose of this study was to evaluate whether edaravone (Radicut®, Mitsubishi Tanabe Pharma Co., Osaka, Japan) injected at the start of reperfusion can suppress myonephropathic-metabolic syndrome (MNMS). MNMS models were made by clamping the bilateral common femoral arteries for 5 hours. At de-clamping (at the start of reperfusion), they were intra-peritoneal injected with 9.0 mg/kg of edaravone (the edaravone group, n?=?5) or an equal volume of saline (the control group, n?=?5). At five hours after de-clamping, the lower extremity muscles were stained with hematoxylin & eosin (H&E) to count the viable cells, and periodic acid- Schiff (PAS) to assess the glycogen storage. The lungs were also stained with H&E to expresse the alveolar wall thickness, and naphthol AS-D chloroacetate esterase to label infiltrating active neutrophils.The viable muscle cells in the edaravone group was significantly greater than that of the control group (593?±?60 vs. 258?±?31 cells/mm2, p?<?0.01). The PAS-positive area in the edaravone group was also significantly higher than that in the control group (30.1?±?6.9 vs. 7.3?±?2.1%, p?<?0.001). The alveolar wall thickness in the edaravone group was significantly lower than that in the control group (63.6?±?5.6 vs. 17.2?±?5.2%, p?<?0.001). The active neutrophil infiltration in the edaravone group was also significantly lower than that in the control group (249?±?59 vs. 68?±?8 cells/mm2, p?<?0.001).We conclude that edaravone injected at the start of reperfusion can suppress not only muscle reperfusion injury but also lung damage. Twit Text FOAVip Edaravone Injected at the Start of Reperfusion Suppresses Myonephropathic Metabolic Syndrome in Rats ????Int J Angiol http://www.kidney.de/pget.php?&tw=1&pmid=25317032 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25317032 #FOAvip English Wikipedia <ref>{{Cite pmid|25317032}}</ref> Edaravone Injected at the Start of Reperfusion Suppresses Myonephropathic Metabolic Syndrome in Rats #MMPMID25317032 Yamamura M; Miyamoto Y; Mitsuno M; Tanaka H; Ryomoto M Int J Angiol 2014[Sep]; 23 (3): 193-6 PMID25317032show ga The purpose of this study was to evaluate whether edaravone (Radicut®, Mitsubishi Tanabe Pharma Co., Osaka, Japan) injected at the start of reperfusion can suppress myonephropathic-metabolic syndrome (MNMS). MNMS models were made by clamping the bilateral common femoral arteries for 5 hours. At de-clamping (at the start of reperfusion), they were intra-peritoneal injected with 9.0 mg/kg of edaravone (the edaravone group, n?=?5) or an equal volume of saline (the control group, n?=?5). At five hours after de-clamping, the lower extremity muscles were stained with hematoxylin & eosin (H&E) to count the viable cells, and periodic acid- Schiff (PAS) to assess the glycogen storage. The lungs were also stained with H&E to expresse the alveolar wall thickness, and naphthol AS-D chloroacetate esterase to label infiltrating active neutrophils.The viable muscle cells in the edaravone group was significantly greater than that of the control group (593?±?60 vs. 258?±?31 cells/mm2, p? äEdaravone Injected at the Start of Reperfusion Suppresses Myonephropat(epmc).pdf DeepDyve Pubget Overpricing